In a secondary analysis of CONFIDENCE (800 adults with CKD and type 2 diabetes), finerenone plus empagliflozin raised odds of a ≥10 mm Hg SBP fall versus finerenone (OR 1.83) but not significantly versus empagliflozin (OR 1.45, P=0.07); benefit seen only if baseline SBP ≥130.
Secondary analysisn = 800
Agarwal et al. Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure